Aura biosciences announces the presentation of phase 2 end of study data evaluating suprachoroidal administration of bel-sar for the first-line treatment of patients with early-stage choroidal melanoma at the retina society annual meeting

Aura will host a virtual ocular oncology investor event featuring key opinion leaders at 8:00 am eastern time on september 12, 2024 aura will host a virtual ocular oncology investor event featuring key opinion leaders at 8:00 am eastern time on september 12, 2024
EML Ratings Summary
EML Quant Ranking